Clinical Trial Update: Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Zanubrutinib, Bendamustine, and Rituximab in previously untreated Waldenström macroglobulinemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Brukinsa (zanubrutinib) (zanubrutinib)
• Rituxan (rituximab) (rituximab)
• Treanda (bendamustine) (bendamustine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: RECRUITING